Obesity

Flagstaff, AZ

92 Obesity Trials near Flagstaff, AZ

Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Ixekizumab + Tirzepatide for Psoriatic Arthritis

Flagstaff, Arizona
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

250 Participants Needed

Tirzepatide for Psoriatic Arthritis

Flagstaff, Arizona
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

200 Participants Needed

Health Promotion Curricula for Obesity Prevention in American Indian Youth

Flagstaff, Arizona
The goal of this study is to learn if a culturally relevant health promotion curricula prevents obesity among 4th graders in rural tribal schools. The main questions it aims to answer are: 1) Does the health promotion curricula intervention increase diet and physical activity behaviors in 4th grade students? Researchers will compare 4th grade classes who will receive intervention at two intervention schools to 4th grades at two comparison schools who will not receive the intervention. All participants will have their skin carotenoids assessed using Veggie Meter, complete 24-hour diet recall via telephone, height and weight measured, body composition, answer two surveys about perceptions of their school environment practices and diet patterns at school, wear accelerometers for 7 days
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 10

120 Participants Needed

mNDPR Diet for Obesity

Flagstaff, Arizona
The investigators propose to conduct a randomized controlled trial with a wait-list control to determine efficacy in reducing risk of obesity and related disease in Native American employees of Twin Arrows Casino. Participants will be randomly assigned to the experimental group or the wait-list control. The experimental group will receive a 12-week mNDPR nutrition intervention with culturally relevant materials. Five NAU Masters of Public Health (MPH) students will be trained in Motivational Interviewing and the mNDPR nutrition protocol to serve as Lifestyle Coaches. These students will lead weekly, group-based coaching sessions with up to 15 participants each at Twin Arrows Casino. Participants will be assigned to their designated group based on their availability. The 12 weekly group sessions will be scheduled to accommodate various work shifts (day, night, and swing). The first group session will be 2-hours long to serve as an 'immersion', followed by weekly 1-hour sessions, all led by the Lifestyle Coaches. The Lifestyle Coaches will use Motivational Interviewing techniques to assist participants to develop personal goals. Lifestyle Coaches will also provide nutrition education, specifically using the mNDPR protocol. Participants in the wait-list control will receive the same intervention after the experimental group completes their 12-week intervention. In addition to measures at weeks 0 and 13, a 24-hour diet recall will be conducted in week 26 for the experimental group to explore long-term durability of diet quality changes.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

146 Participants Needed

BI 456906 for Diabetes and Obesity

Phoenix, Arizona
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

755 Participants Needed

BI 456906 for Obesity

Phoenix, Arizona
This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

726 Participants Needed

Retatrutide for Obesity

Phoenix, Arizona
This trial is testing a weekly medication called retatrutide. It aims to help people who are overweight or obese and have knee osteoarthritis. The study will last over a year to see if the medication is safe and effective.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

405 Participants Needed

Exercise + Amino Acid Infusion for Obesity

Scottsdale, Arizona
Maintenance of protein homeostasis is impaired in skeletal muscle of humans with obesity. A hallmark of this defect is distorted expression of isoforms of the myosin heavy chain (MHC) protein, and this defect is linked to obesity-associated adverse health outcomes. By employing exercise and increase in plasma amino acids as investigational tools the investigators intend to modulate the metabolism of muscle MHC isoforms in order to unravel the biological mechanisms that sustain distorted MHC protein metabolism in muscle of humans with obesity.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45

94 Participants Needed

Endoscopic Gastric Mucosal Ablation for Obesity

Scottsdale, Arizona
This trial is testing a new non-surgical weight loss method called GMA for obese people. It uses a tube with a camera to treat the stomach lining with argon gas and waterjet, which helps reduce hunger hormones.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22 - 60

15 Participants Needed

LY3305677 for Obesity

Scottsdale, Arizona
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

1217 Participants Needed

Retatrutide for Obesity

Phoenix, Arizona
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2300 Participants Needed

Retatrutide for Chronic Kidney Disease and Obesity

Scottsdale, Arizona
This trial is testing a medication called retatrutide to see if it can help improve kidney function. The study focuses on people who are overweight or obese and have chronic kidney disease, with or without Type 2 Diabetes. The goal is to find out if this medication can make their kidneys work better.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

146 Participants Needed

Muscle Assessment Score for Liver Transplant Outcomes

Phoenix, Arizona
Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

100 Participants Needed

Inclisiran for Cardiovascular Disease Prevention

Glendale, Arizona
This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79

14082 Participants Needed

Retatrutide for Obesity

Scottsdale, Arizona
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+

10000 Participants Needed

Orforglipron for Type 2 Diabetes and Obesity

Phoenix, Arizona
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2749 Participants Needed

Tirzepatide for Obesity

Phoenix, Arizona
This trial is testing tirzepatide, a medication that helps control blood sugar and reduce appetite, to see if it can lower health problems and death rates in adults who are very overweight. Tirzepatide was developed by Eli Lilly to improve blood sugar control in adults with type 2 diabetes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+

15374 Participants Needed

Setmelanotide for Obesity

Scottsdale, Arizona
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * POMC or PCSK1 (Sub-study 035a) * LEPR (Sub-study 035b) * SRC1 (Sub-study 035c) * SH2B1 (Sub-study 035d) The objectives and endpoints are identical for these sub-studies.
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 65

400 Participants Needed

Tirzepatide for Psoriasis and Obesity

Scottsdale, Arizona
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

200 Participants Needed

LY3549492 for Obesity

Scottsdale, Arizona
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

275 Participants Needed

Why Other Patients Applied

"I am applying for my daughter. She turns 12 this year and is overweight. She's 5'4" and 176 pounds. Would be great to enroll her in a clinical trial to see if this form of care could work for her. Realize that there's no guarantee, but I support her and we'd like to give it a try."

MW
Parent of PatientAge: 46

"I have tried to lose weight, but as I get older, it becomes harder and harder. I have lost weight in the past through diet and exercise, but it has been more difficult to accomplish as I age."

JP
Obesity PatientAge: 44

"I have a heart condition, and my fat is all in my chest, surrounding my heart. It's hard for me to exercise because my legs are thin and the upper body weight is too much — putting strain on my leg joints. It’s a vicious cycle. I am also post-menopausal, which adds additional weight loss difficulty. I also have stress with being a full time caregiver for my mom. I'm interested in trying a clinical trial."

DK
Obesity PatientAge: 56

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I need to lose weight because it's affecting my knees. I've already had a knee replacement and the second one is happening on the left knee in a few months. I've participated in a study in the past for a skin-related issue, and had a good experience. That's why I'm interested in joining a study for wieght loss."

KI
Obesity PatientAge: 69

LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

Scottsdale, Arizona
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

350 Participants Needed

LY3841136 for Obesity

Scottsdale, Arizona
This trial is testing a new medication called LY3841136 to help adults who are overweight or obese manage their weight. The study aims to see if this medication is safe and effective over several months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

263 Participants Needed

LY3305677 for Obesity

Scottsdale, Arizona
This trial is testing a new medication called LY3305677 to help adults who are obese or overweight manage their weight. The study will last over a year. Researchers want to see if this medication helps people lose weight and if it is safe to use.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

179 Participants Needed

AMG 133 for Obesity With or Without Type 2 Diabetes

Scottsdale, Arizona
This trial is testing AMG 133, a new drug, to see if it helps people lose weight and keep it off. It targets overweight or obese individuals, both with and without Type 2 diabetes. The drug may work by affecting metabolism or appetite.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

592 Participants Needed

Revita DMR for Obesity

Scottsdale, Arizona
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both a midpoint analysis and a pivotal analysis. Patients who previously lost at least 15% of their body weight on a GLP-1 can qualify for the open label REVEAL-1 cohort. The data generated from the REVEAL-1 cohort will be used for open label reporting as the study progresses. The REMAIN-1 randomized cohort will enroll patients living with obesity and a body mass index ("BMI") between 30 and 45 kg/m2 who are not currently on a GLP-1 drug. Patients will be prescribed tirzepatide and titrated to achieve at least 15% total body weight loss, at which time tirzepatide will be discontinued and patients will be randomized to Revita versus sham at 2:1. Midpoint Analysis of Randomized Cohort: The midpoint analysis of the randomized cohort will be performed at three months of follow-up on approximately 45 patients, allowing us to assess and report on safety and efficacy signals that could be anticipated in the pivotal analysis. These patients are distinct from those included in the pivotal analysis. Pivotal Analysis of Randomized Cohort: The pivotal analysis of the randomized cohort will be performed on approximately 315 patients (distinct from those included in the midpoint analysis) and will evaluate safety and efficacy in the first co-primary endpoint, which is weight regain from the time of tirzepatide discontinuation in Revita DMR versus sham patients at six months, with a primary objective of demonstrating a benefit of Revita DMR versus sham for weight maintenance after GLP-1 discontinuation. The second co-primary endpoint evaluates a responder rate among the Revita DMR treated group at one year to demonstrate the durability of the Revita DMR procedure for weight maintenance after discontinuation of a GLP-1-based therapy. Secondary objectives will include evaluation of the effectiveness of the Revita DMR procedure on the change in blood glucose levels, cardiovascular disease ("CVD") risk factors, body composition and pre-diabetes status. All patients enrolled in the study will receive diet and lifestyle counseling.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21 - 70

315 Participants Needed

Endoscopy Sleeve Gastroplasty for Insulin Resistance and Obesity

Scottsdale, Arizona
The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils (EOS), and adipose tissue (AT) in human health and in disease states such as obesity and insulin resistance.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

12 Participants Needed

Long-Term Setmelanotide for Obesity

Scottsdale, Arizona
This is a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in patients who have completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:2 - 65

300 Participants Needed

Gastric Balloon for Obesity

Scottsdale, Arizona
This trial tests a stomach device and a healthy lifestyle program to help adults with obesity lose weight. The device makes people feel full sooner, and the program supports better eating and exercise habits.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:22 - 65

1000 Participants Needed

Orforglipron for Obesity

Sun City West, Arizona
This trial will test the safety and effectiveness of an oral medication called orforglipron in adults who are obese or overweight and have related health problems. The medication aims to help reduce body weight by possibly affecting appetite or metabolism.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

3127 Participants Needed

Orforglipron for Obesity

Sun City West, Arizona
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1200 Participants Needed

1234

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Obesity clinical trials in Flagstaff, AZ pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Obesity clinical trials in Flagstaff, AZ work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Obesity trials in Flagstaff, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Flagstaff, AZ for Obesity is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Flagstaff, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Obesity medical study in Flagstaff, AZ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Obesity clinical trials in Flagstaff, AZ?

Most recently, we added Nutrition & Exercise Prehabilitation for Obesity-Related Cancer, Cagrilintide for Obesity and Type 2 Diabetes and Macupatide + Eloralintide for Obesity to the Power online platform.

What is the new treatment for obesity?

The “new” treatments are weekly injections of GLP-1–based drugs such as semaglutide (Wegovy) and the dual GIP/GLP-1 drug tirzepatide (Zepbound), which curb appetite and slow stomach emptying; in large trials they helped adults lose roughly 15-22 % of their starting weight over 12–18 months when combined with diet and exercise. They are prescription-only, must be used long-term to keep the weight off, and while most side-effects are mild stomach upset, they can be expensive and require close medical follow-up—so you and your clinician should weigh these pros and cons against other options like older pills, bariatric surgery, and structured lifestyle programs.

How much do I get paid for a clinical trial?

There is no single rate, but in the U.S. healthy-volunteer Phase I studies usually pay about $75–$150 for a short outpatient visit or $300–$500 per overnight, adding up to roughly $1,500–$6,000 for a multi-day study; later-phase trials for people who already have the illness typically offer a smaller stipend—often $25–$100 per visit—plus travel reimbursement. Amounts are set case-by-case by the study sponsor and ethics board, based on the time you give up, the inconvenience or discomfort involved (blood draws, overnight stays, special diets), and any out-of-pocket costs, and they must be prorated so you can stop at any time and still receive payment for the visits you’ve completed.

How much weight can you lose with ESG surgery?

Large studies find that people lose roughly 15–20 % of their starting weight after endoscopic sleeve gastroplasty—about 30–50 lb if you begin at 200–250 lb—and most keep the bulk of that off for at least two years when they stay in a structured nutrition and activity program. Your exact result can be higher or lower depending on your initial BMI, how closely you follow the dietary and lifestyle plan, and whether you attend regular follow-up visits with the bariatric team.

What weight is considered obese?

For adults, obesity starts at a body-mass index (BMI) of 30 kg/m²—so take your height in metres, square it, and multiply by 30 to see the weight cut-off. Example: 5′4″ (1.63 m) → 1.63² × 30 ≈ 88 kg / 194 lb; 6′0″ (1.83 m) → 1.83² × 30 ≈ 102 kg / 225 lb. BMI is only a quick gauge—muscle mass, ethnicity, waist size, and other health factors matter too—so use it as a starting point and confirm risks with your healthcare professional.

Who is eligible for tirzepatide?

Tirzepatide is eligible for adults in two settings: (1) as Mounjaro to improve blood-sugar control in type-2 diabetes, and (2) as Zepbound for weight management if you have obesity (BMI ≥ 30) or are overweight (BMI ≥ 27) with at least one related condition such as high blood pressure, abnormal cholesterol, sleep apnea, heart disease, or type-2 diabetes. You are NOT a candidate if you’re pregnant, under 18, or have a personal or family history of medullary thyroid cancer or MEN-2; your doctor will also screen for issues like pancreatitis, severe stomach problems, or other risks before prescribing. In short, meeting the diabetes or weight criteria and having no major contraindications makes you a potential candidate, but final approval comes after a thorough medical review.

What tests are done for unexplained weight gain?

Doctors usually start with a history and physical exam, then order a small “baseline” panel—complete blood count, comprehensive metabolic panel (kidney + liver), fasting glucose/HbA1c, cholesterol, thyroid-stimulating hormone, and a pregnancy test in women of child-bearing age. If exam findings point to a specific cause, they add focused tests: e.g., cortisol or prolactin for suspected hormone tumors, sex-hormone and ultrasound for possible PCOS, heart or kidney studies for fluid retention, or imaging of the pituitary/adrenal glands. In short, everyone gets the core labs, and any further blood work or scans are chosen only when your symptoms or medications suggest a particular problem.

Can a morbidly obese person lose weight without surgery?

Yes. Rigorous studies show that people with class III (“morbid”) obesity can shed 6-8 % of their starting weight through weekly lifestyle-coaching programs, and often 15-20 % when the same program is paired with new once-a-week injections such as semaglutide (Wegovy) or tirzepatide (Zepbound); endoscopic sleeve procedures add another non-surgical option in the same range. Because even a 5-10 % loss markedly improves blood pressure, diabetes and sleep-apnea, doctors usually start with dietitian-guided eating plans, gradual activity and behaviour counselling, then add medication if weight hasn’t dropped by about 5 % after three months—saving surgery for those who still need more help.

How to get rid of fat deposits on legs?

You can’t melt fat from your legs alone, so aim for gradual overall weight loss (a modest calorie deficit built around whole foods) while doing both full-body cardio and leg-strength exercises such as squats or lunges 2-3 times a week—the combo burns calories and builds muscle that makes legs look firmer as fat comes off. If your legs stay disproportionately large, painful or bruise easily, ask a clinician about lipedema or other medical causes, because lifestyle changes help most people but specialised treatment is sometimes needed.

How to get Ozempic for weight loss?

Ozempic (semaglutide) can be prescribed for weight loss, but it is technically an off-label use; most clinicians instead start with the weight-loss version of the same drug, Wegovy. To pursue either one, confirm you meet typical criteria (BMI ≥30, or ≥27 with a weight-related condition), then see a primary-care doctor, endocrinologist, or an obesity-medicine/telehealth service that can review your labs, rule out contraindications, and submit any required prior-authorization to your insurer or the manufacturer’s savings program. Expect a gradual dose-escalation schedule, routine follow-ups for side-effects such as nausea, and the need to pair the medication with diet and activity changes to maintain the ~15 % average weight loss seen in clinical trials.

Which drink is good for belly fat loss?

No drink can “melt” belly fat on its own; losing abdominal fat still comes down to taking in fewer calories than you burn. The most studied helpers are plain water (pre-meal water can curb appetite), unsweetened green tea or black coffee (their caffeine and, for green tea, catechins give a small metabolic boost). Choose these without added sugar, pair them with balanced meals and regular exercise, and they can support—rather than drive—belly-fat loss.

Popular Searches

By Condition

Depression Clinical Trials in Arizona

Anxiety Clinical Trials in Arizona

Schizophrenia Clinical Trials in Arizona

ADHD Clinical Trials in Arizona

Bipolar Disorder Clinical Trials in Arizona

Multiple Sclerosis Clinical Trials in Arizona

Autism Clinical Trials in Arizona

Treatment Resistant Depression Clinical Trials in Arizona

Borderline Personality Disorder Clinical Trials in Arizona

Social Anxiety Disorder Clinical Trials in Arizona

Parkinson's Disease Clinical Trials in Arizona

Alzheimer's Disease Clinical Trials in Arizona

By Location

Clinical Trials near Phoenix, AZ

Clinical Trials near Tucson, AZ

Clinical Trials near Scottsdale, AZ

Clinical Trials near Mesa, AZ

Clinical Trials near Chandler, AZ

Clinical Trials near Tempe, AZ

Clinical Trials near Gilbert, AZ

Clinical Trials near Glendale, AZ

Clinical Trials near Peoria, AZ

Clinical Trials near Sun City, AZ

Clinical Trials near Goodyear, AZ

Clinical Trials near Flagstaff, AZ

Other People Viewed

By Subject

192 Clinical Trials near Highland Park, IL

Top Clinical Trials near Folsom, CA

Top Pediatric Cancer Clinical Trials

Top Clinical Trials near Atherton, CA

Top Clinical Trials near Huntington, NY

Top Diabetes Clinical Trials near Chicago, IL

19 Glaucoma Trials near Los Angeles, CA

Top Idiopathic Intracranial Hypertension Clinical Trials

Top Ovarian Cancer Clinical Trials

Top Clinical Trials near Culver City, CA

Top Liver Fibrosis Clinical Trials

Top Clinical Trials near Hudson, NY

By Trial

enVista EY Beyond Lens for Cataracts

CAR T-Cell Therapy for Liver Cancer

Drug Effects for Postural Orthostatic Tachycardia Syndrome

Endocrine Therapy for Breast and Prostate Cancer

MultiStem for Trauma-Induced Multiple Organ Failure

SC Pembrolizumab + Hyaluronidase for Non-Small Cell Lung Cancer

Aortic Valve-in-Valve for Aortic Stenosis

NEXUS Stent Graft for Aortic Disease

Mobile Education App for Childhood Epilepsy

Elafibranor for Primary Biliary Cholangitis

Olaparib for Advanced Cancer

Educational Video for Laparoscopic Hysterectomy

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial